Lantana Spa Offers a Look into the CBD Trend at Hotel Spas
By Shane Kelly Spa Director, JW Marriott San Antonio | August 25, 2019
In recent years, the Lantana Spa team at JW Marriott San Antonio Hill Country Resort & Spa has seen the spa and wellness industry growing exponentially. Hotel and resort spas were once after-thoughts or just an added amenity of the hotel. Now, they have not only become a major revenue source but a necessity for potential guests searching where to book their stays.
The spa industry grew by 6.4% annually from 2015–2017, from a $3.7 to a $4.2 trillion market, nearly twice as fast as global economic growth. Wellness tourism is a $639 billion market in 2017, projected to reach $919 billion by 2022. Wellness tourism grew by 6.5% annually from 2015–2017, more than twice as fast as tourism overall (3.2% annually, based on Euromonitor data) (McGroarty, 2018).
The evolution of the spa industry is an ongoing, cyclical process of trying to find the next hot trend that consumers are looking for. Perennial topics always include the latest in youth and anti-aging treatments for skincare, while the newest in cosmetics such as Brazilian blowouts or dip powder nails provide new sources of inspirations for new treatments for consumers. This constant change in trends and fads in marketing by the beauty industry has traditionally led to prevailing with their products over conventional, holistic alternatives.
JW Marriott San Antonio Hill Country Resort & Spa
However, precipitated by change in federal legislation leading to what is arguably one of the hottest and most controversial trends in the beauty, health, and wellness market today is non-psychoactive cannabinoids (CBDs).
Cannabis use has seen varying degrees of legalization despite ongoing regulation at the federal level, and this partial decriminalization has been the catalyst for what has been a boom in the study of the hemp plant for alternative medicinal benefits. The popularity of the CBDs as both a topical and oral agent to combat afflictions such as chronic pain and anxiety is well documented in both historical anecdotal evidence, but also more recently in more rigorously controlled instances (see "Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain," Bannister et al, 2019).